ALBI and PALBI Scores and HCC Prognosis

Assessment of Prognostic Accuracy of Albumin-Bilirubin and Platelet-Albumin-Bilirubin Grades in Hepatocellular Carcinoma Patients According to Different Treatment Modalities

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05720195

Enrollment

645

Registered

2023-02-09

Start date

2019-01-01

Completion date

2022-12-31

Last updated

2023-02-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular Carcinoma (HCC) Prognosis

Brief summary

To compare the predictive ability of ALBI and PALBI grades with CTP and MELD scores. To investigate the efficacy of ALBI and PALBI grades for predicting the prognosis of HCC and overall survival among different modalities of treatment.

Interventions

DIAGNOSTIC_TESTALBI

Albumin-Bilirubin and Platelet-Albumin-Bilirubin Grades for prognosis of HCC

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 99 Years

Healthy volunteers

Inclusion criteria

• The diagnosis of HCC will be based on the presence of an arterial hypervascular focal lesion \> 2 cm with rapid wash-out with a single imaging modality (triphasic computed tomography (CT), or dynamic magnetic resonance imaging (MRI)) or two imaging modalities demonstrating the before mentioned feature for lesions \< 2 cm with or without elevated serum alpha-fetoprotein (AFP) levels.

Exclusion criteria

* Patients below 18 years old. * Patients with pre-existing other malignancies. * Patients with pre-existing gall bladder stones, benign strictures, or other biliary diseases. * Patients with pre-existing haematologic disorders. * Patients with proteinuria. * Missed follow-up.

Design outcomes

Primary

Measure	Time frame	Description
Overall survival among HCC patients as assessed by the albumin-bilirubin (ALBI) score	2 years	We will compare the ability of ALBI score to predict overall survival among HCC patients versus Child Pugh and MELD scores
Overall survival among HCC patients as assessed by the platelet-albumin-bilirubin (PALBI) score	2 years	We will compare the ability of PALBI score to predict overall survival among HCC patients versus Child Pugh and MELD scores

Secondary

Measure	Time frame	Description
Overall survival among HCC patients according to treatment modality as assessed by the albumin-bilirubin (ALBI) score	2 years	We will compare the ability of ALBI score to predict overall survival among HCC patients stratified according to treatment modality (Surgical resection, local ablation, trans-arterial chemoembolization, sorafenib and best supportive care)
Overall survival among HCC patients according to treatment modality as assessed by the platelet-albumin-bilirubin (PALBI)	2 years	We will compare the ability of PALBI score to predict overall survival among HCC patients stratified according to treatment modality (Surgical resection, local ablation, trans-arterial chemoembolization, sorafenib and best supportive care)

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026